Lv1
18 积分 2024-03-07 加入
Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care
2天前
已完结
How a potent immune therapy loses its punch against a blood cancer
1个月前
已完结
Cytokine-mediated CAR T therapy resistance in AML
1个月前
已完结
Single-cell meta-analysis of inflammatory bowel disease with scIBD
1个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
2个月前
已完结
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer
2个月前
已完结
the type2
2个月前
已完结
TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn’s disease
2个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
3个月前
已完结
Risankizumab versus ustekinumab for Crohn’s disease: a phase IIIb study
3个月前
已完结
皖公网安备34019202002308
